the independent lab that raised the alarm about Zantac’s cancer risks in 2019. GSK’s American depositary receipts fell 1.7% on the news before bouncing to $44.59 at the close in New York trading.

It follows concern in several countries over the presence of impurities in Zantac and other ranitidine products. Canada and France have already announced Zantac recalls. The US and the European ...